Clinical Trials and Evidence Gaps

ACC overview

Adrenocortical carcinoma (ACC) is a rare endocrine malignancy for which clinical trials and evidence synthesis are constrained by low incidence, heterogeneous presentation, and frequent reliance on retrospective or multinational cooperative datasets rather than large randomized studies.¹ Within ACC care, this problem affects nearly every stage of management, including decisions about surgery, adjuvant treatment, systemic therapy for advanced disease, and biomarker development. The resulting literature often mixes formal trials, registry analyses, consensus-oriented reviews, and indirect evidence, which can make standards of care difficult to define with the same confidence seen in more common solid tumors.¹

The ACC trial landscape is therefore characterized less by an abundance of competing high-level evidence than by persistent structural evidence gaps. Small sample sizes, variable eligibility criteria, inconsistent endpoint selection, and differences in pathology review or stage distribution may all limit cross-study comparability. In practice, this means that many published findings may be hypothesis-generating rather than definitive, and treatment recommendations often depend on extrapolation, expert consensus, and multidisciplinary judgment rather than repeated confirmatory trials.¹

A further limitation is that the published record itself requires careful appraisal. In a rare cancer literature with relatively few pivotal studies, problems such as source-text mismatch, publication-format ambiguity, or editorial corrections can have outsized effects on interpretation even when they do not alter clinical data directly.¹² For researchers, this makes methodological rigor and transparent reporting central parts of the evidence base, not merely background concerns.

Diagnostic Context for the Evidence Base

ACC research is shaped by rarity at both the patient and institutional levels. Most centers see limited numbers of cases, and available cohorts may be enriched for referral complexity, advanced disease, or highly selected surgical populations. This may improve expertise within specialty centers but may also reduce generalizability to broader practice settings.¹

The most reliable conclusion from this literature is that single-center experience alone is usually insufficient to answer major treatment questions in ACC. What remains less reliable is the apparent precision of estimates derived from very small cohorts or incompletely harmonized datasets. Clinically, this supports referral to experienced centers and cautious interpretation of institution-specific outcomes.

Major Evidence Gaps

Underpowered Trials and Heterogeneous Cohorts

Underpowering remains a central limitation in ACC trials and observational studies. Slow accrual, broad clinical heterogeneity, and differing prior-treatment histories may obscure treatment effects or make negative studies difficult to interpret. Even when cooperative groups are involved, sample sizes may remain modest relative to the biologic and clinical diversity of the disease.¹

This makes broad claims of equivalence or superiority difficult to establish. Reliable signals may still emerge for feasibility, safety, or directional efficacy, but the practical implication is that many apparent outcome differences should be treated as provisional unless reproduced across settings.

Endpoint Selection and Study Architecture

Because overall survival can be difficult to study efficiently in a rare cancer with variable treatment sequences, ACC studies often depend on surrogate or intermediate endpoints. However, inconsistency in endpoint definitions, imaging schedules, and censoring rules may reduce interpretability across studies. Biomarker stratification is also appealing but remains difficult to operationalize when tissue availability, assay standardization, and prospective validation are limited.¹

The most dependable principle is that trial architecture matters substantially in ACC, sometimes as much as the intervention being tested. What is less dependable is the assumption that outcomes from differently designed studies can be compared directly. For management and research planning, this argues for more standardized eligibility criteria, endpoint definitions, and correlative-study frameworks.

Trial Infrastructure and Research Networks

These structural problems have increased the importance of international collaboration and rare-tumor research networks. In ACC, multicenter coordination may improve accrual, support central review, and allow more consistent collection of biologic and clinical variables. Such networks are also important for testing whether biomarker-informed treatment strategies are feasible in real-world rare-cancer workflows.¹

The strongest evidence here supports the value of cooperative infrastructure itself, rather than any single universal trial model. What remains uncertain is how quickly networked studies can generate practice-changing evidence in a disease with few eligible patients and evolving standards. The practical implication is that trial participation, where feasible, remains an important component of ACC care and research.

Interpretation Pitfalls

The limitations of the ACC evidence base are not only statistical but also editorial and methodological. In a small literature, errors in citation alignment, article labeling, or publication format may alter how evidence is weighted, even when no new clinical data are introduced.¹² Historical or niche reports may still be useful for context, but they rarely resolve major therapeutic uncertainties on their own.

This means that the most reliable use of the literature is usually in synthesis rather than in isolated reading of individual papers. What is not reliable is overinterpreting single reports, corrections, or indirect evidence as if they materially redefine treatment standards. For researchers, source verification and careful classification of article type are essential before incorporating findings into broader conclusions.

Role in Management and Research

Taken together, the ACC trials literature supports a trial-oriented and center-based approach to care, while also showing why progress has been slow. Compared with common malignancies, ACC management is more often shaped by constrained evidence, selective cohorts, and incomplete biomarker validation than by multiple large confirmatory studies.¹ This affects not only drug development but also comparative assessment versus surgery, local therapies, and multimodal treatment pathways.

The most dependable practical conclusion is that future progress will likely depend on harmonized international study design, prospective biospecimen integration, and clearer separation of exploratory from confirmatory evidence. What remains uncertain is which specific therapeutic strategies will ultimately prove most effective once tested under these improved conditions. As a result, ACC research is defined as much by the need to strengthen evidence-generation methods as by the search for new interventions themselves.¹

Included Articles

• PMID 35639986: A published erratum corrected the labeling and title of a response regarding cytoreductive surgery in metastatic ACC, but did not contribute new outcome data. Its main relevance is editorial, underscoring the need to read this literature carefully in context.²

PMID 34273795

PMID 34273795 cannot be integrated on the basis of the provided excerpt because the local content appears to be unrelated philosophical text rather than the cited ACC study on non-operative management of resectable adrenocortical carcinoma. If the article is confirmed and reviewed from the correct source, it could be relevant to evidence gaps around treatment selection and real-world management, but the present mismatch requires explicit caution before using it to support any ACC-specific claim.¹

• PMID 34273795: PMID 34273795 is listed as an ACC management study, but the supplied excerpt does not match that citation and therefore cannot currently be summarized as clinical evidence. Its immediate relevance is methodological: it highlights the need to verify source-text alignment before incorporating literature into a small and heterogeneous ACC evidence base.¹

References

Footnotes

1. Factors Associated with Non-Operative Management of Resectable Adrenocortical Carcinoma.. J Surg Res. 2021. PMID: 34273795. Local full text: 34273795.md ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹² ↩¹³

2. Correction to: Response to Letter to the Editor from de Ponthaud et al: “Cytoreductive Surgery of the Primary Tumor in Metastatic Adrenocortical Carcinoma: Impact on Patients’ Survival”.. J Clin Endocrinol Metab. 2022. PMID: 35639986. Local full text: 35639986.md ↩ ↩² ↩³